Viral respiratory infections, which account for over $50 billion annually in the United States, often predispose patients to respiratory bacterial infection. Morbidity and mortality are exacerbated by concurrent infections of the respiratory tract, and similar symptoms demand a need to correctly identify the causal pathogen(s). Swift and accurate recognition of viruses and bacteria lead to antibiotic stewardship, economical treatment, and reduced patient recovery time. MD Labs’ Respiratory Tract Microbiota (RTM) testing targets use a multiplex real-time polymerase chain reaction (RT-PCR) to simultaneously detect the most common deleterious organisms in the respiratory tract. RT-PCR is an advanced technology that yields superior specificity, sensitivity, accuracy, and timeliness compared to traditional methods. We offer flexible, custom testing to deliver the highest-quality and cost-effective results.


Coronavirus disease 2019 (COVID‑19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Our laboratory utilizes the latest molecular technologies to test for SARS-CoV-2. We operate under the quality standards of the FDA, CAP, and CLIA. COVID-19 testing is available with a self-pay price of $100.

Commonly found Respiratory pathogens include:


  • Bordetella (PAN)
  • Bordetella pertussis
  • Chlamydophila pneumoniae
  • Haemophilus influenzae
  • Klebsiella pneumoniae
  • Legionella pneumophila
  • Mycoplasma pneumoniae
  • Staphylococcus aureus
  • Streptococcus pneumoniae